The current state of prostate-specific antigen testing

Ryan Lewis, Brad Hornberger

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Since prostate-specific antigen (PSA) testing was approved in 1994, the incidence of metastasis and mortality from prostate cancer have significantly decreased. However, PSA screening for prostate cancer has limitations and few large randomized controlled trials have been conducted to determine the mortality benefit of PSA screening. Two studies that have been conducted are the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). These were the two main studies the US Preventive Services Task Force (USPSTF) used in its recommendation against prostate cancer screening in 2012. However, new evidence has demonstrated that the PLCO trial had significant limitations and the results of the ERSPC trial were more significant than previously thought. This article describes the strengths and weaknesses of the USPSTF's recommendation, along with current guidelines for prostate cancer screening.

Original languageEnglish (US)
Pages (from-to)51-53
Number of pages3
JournalJournal of the American Academy of Physician Assistants
Issue number9
StatePublished - 2016


  • Guidelines
  • PSA
  • Prostate cancer
  • Prostate-specifi c antigen
  • Testing
  • US Preventive Services Task Force

ASJC Scopus subject areas

  • Nurse Assisting


Dive into the research topics of 'The current state of prostate-specific antigen testing'. Together they form a unique fingerprint.

Cite this